A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report

Sorokins, Vladimirs; Tilgase, Andra; Olmane, Evija; Isajevs, Sergejs; Zablocka, Tatjana; Rasa, Agnija; Alberts, Pēteris

doi:10.1177/2050313x20934978

Cited by 2 publications

(1 citation statement)

References 11 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, a total of four OV products have been approved for marketing: Rigvir (SND005), Oncorine (H101), Imlygic (Talimogene laherparepvec, T-VEC) and Delytact (teserpaturev/G47Δ). Rigvir is an unmodified enteric cytopathic human orphan virus type 7 (ECHO-7), approved for the treatment of melanoma [306][307][308][309][310][311] in Latvia in 2004, 312 making it the first approved oncolytic drug. Later in 2006, the adenovirus-H101 was approved in China, 13 for squamous cell cancer of head and neck or esophagus.…”

Section: Clinical Trials Of Ovsmentioning

confidence: 99%

Oncolytic virotherapy: basic principles, recent advances and future directions

Lin

Shen

Liang

2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

Oncolytic viruses (OVs) have attracted growing awareness in the twenty-first century, as they are generally considered to have direct oncolysis and cancer immune effects. With the progress in genetic engineering technology, OVs have been adopted as versatile platforms for developing novel antitumor strategies, used alone or in combination with other therapies. Recent studies have yielded eye-catching results that delineate the promising clinical outcomes that OVs would bring about in the future. In this review, we summarized the basic principles of OVs in terms of their classifications, as well as the recent advances in OV-modification strategies based on their characteristics, biofunctions, and cancer hallmarks. Candidate OVs are expected to be designed as “qualified soldiers” first by improving target fidelity and safety, and then equipped with “cold weapons” for a proper cytocidal effect, “hot weapons” capable of activating cancer immunotherapy, or “auxiliary weapons” by harnessing tactics such as anti-angiogenesis, reversed metabolic reprogramming and decomposing extracellular matrix around tumors. Combinations with other cancer therapeutic agents have also been elaborated to show encouraging antitumor effects. Robust results from clinical trials using OV as a treatment congruously suggested its significance in future application directions and challenges in developing OVs as novel weapons for tactical decisions in cancer treatment.

show abstract

Section: Clinical Trials Of Ovsmentioning

confidence: 99%

Oncolytic virotherapy: basic principles, recent advances and future directions

Lin

Shen

Liang

2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

The Value of Histopathological Characteristics and BRAF and NRAS Mutations for the Diagnosis, Risk Stratification, and Prognosis of Malignant Invasive Melanoma

Zablocka¹,

Isajevs²

2023

Melanoma - Standard of Care, Challenges, and Updates in Clinical Research

Self Cite

View full text Add to dashboard Cite

In recent years, the direction of personalized medicine, which is based on a disease-specific targeting therapy, as well as the early diagnosis of tumors and the identification of high-risk individuals, is rapidly developing in the world. Invasive melanoma is a tumor with high impact for its rapidly growing incidence, high mortality, increased complexity, and high care costs in advanced stages. Recent studies demonstrated the significant value of both conventional histopathological characteristics and genetic alterations in melanoma. This review focuses on the value of conventional histopathological characteristics including histological tumor subtype, Clark level, Breslow thickness, solar elastosis, ulceration, regression, lymphovascular invasion, mitotic counts, peritumoral lymphocyte infiltration, clinical characteristics such as age, gender, length of follow-up after surgery, recurrence, or metastasis, and progression-free survival, and tumor BRAF and NRAS mutations.

show abstract

A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report

Cited by 2 publications

References 11 publications

Oncolytic virotherapy: basic principles, recent advances and future directions

Oncolytic virotherapy: basic principles, recent advances and future directions

The Value of Histopathological Characteristics and BRAF and NRAS Mutations for the Diagnosis, Risk Stratification, and Prognosis of Malignant Invasive Melanoma

Contact Info

Product

Resources

About